Document is current
Any future updates will be listed below
-
Authors
Lu, Scott
Peluso, Michael J. http://orcid.org/0000-0003-0585-6230
Glidden, David V.
Davidson, Michelle C. http://orcid.org/0000-0002-5518-9774
Lugtu, Kara
Pineda-Ramirez, Jesus
Tassetto, Michel
Garcia-Knight, Miguel
Zhang, Amethyst
Goldberg, Sarah A. http://orcid.org/0000-0002-8642-1468
Chen, Jessica Y. http://orcid.org/0000-0002-4491-2584
Fortes-Cobby, Maya
Park, Sara
Martinez, Ana
So, Matthew
Donovan, Aidan
Viswanathan, Badri http://orcid.org/0009-0001-4779-5037
Hoh, Rebecca
Donohue, Kevin http://orcid.org/0000-0002-4237-5957
McIlwain, David R.
Gaudiliere, Brice http://orcid.org/0000-0002-3475-5706
Anglin, Khamal
Yee, Brandon C. http://orcid.org/0000-0003-4649-7975
Chenna, Ahmed
Winslow, John W.
Petropoulos, Christos J. http://orcid.org/0000-0001-5496-8090
Deeks, Steven G. http://orcid.org/0000-0001-6371-747X
Briggs-Hagen, Melissa
Andino, Raul http://orcid.org/0000-0001-5503-9349
Midgley, Claire M. http://orcid.org/0000-0001-5196-4713
Martin, Jeffrey N. http://orcid.org/0000-0002-9773-3256
Saydah, Sharon http://orcid.org/0000-0002-6350-5300
Kelly, J. Daniel http://orcid.org/0000-0002-7616-0321
- License Information
-
More Information
Article History
Received: 22 July 2023
Accepted: 19 August 2024
First Online: 29 August 2024
Competing interests
: MJP has received consulting fees from Gilead Sciences, AstraZeneca, BioVie, Apellis Pharmaceuticals, and BioNTech and research support from Aerium Therapeutics, outside the submitted work. SGD reports consulting for Enanta Pharmaceuticals and Pfizer and reports research support from Aerium Therapeutics outside the submitted work. The remaining authors declare no competing interests.
